January 30, 2019
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Read More
January 30, 2019
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
Read More
January 30, 2019
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
Read More
January 30, 2019
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
Read More
January 30, 2019
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
Read More
January 30, 2019
Telaprevir Open-Label Study in Co-Infected Patients
Read More
January 30, 2019
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
Read More
January 30, 2019
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
Read More
January 30, 2019
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
Read More
January 30, 2019
Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C – An Observational Study in Germany (LIFE-C)
Read More
January 30, 2019
Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C – An Observational Study in Germany (LIFE-C)
Read More
January 30, 2019
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Read More
Load More
X